Pharmaceutical compositions comprising colloidal silicon dioxide

CAFC
  • US 8,617,598 B2
  • Filed: 06/05/2012
  • Issued: 12/31/2013
  • Est. Priority Date: 09/28/2001
  • Status: Active Grant
First Claim
Patent Images

1. A pharmaceutical composition in the form of a dispersible tablet to be dispersed in an ingestible liquid before administration to a patient, comprising a solid dispersion of 40-O-(2-hydroxy)ethyl-rapamycin, a disintegrant comprising cross-linked polyvinylpyrrolidone and colloidal silicon dioxide, wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight and 10 to 30% of cross-linked polyvinylpyrrolidone by weight, and wherein the tablet has a disintegration time of 3 minutes or less and a hardness of 35 to 80N.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×